Guidelines For Treatment Of Osteoporosis Research Articles

Global current research status and future hotspots in osteoporotic fracture based on bibliometric assessment and visualization techniques.

In the past decade, the evolution of themes in the field of osteoporotic fractures has changed from epidemiology and prediction of long-term morbidity, risk assessment of osteoporotic fractures, and zoledronic acid and denosumab in the treatment of osteoporosis to treatment guidelines for osteoporosis and the side effects caused by anti-osteoporotic drugs. To understand the trends and hotspots in osteoporotic fracture research. Original articles were retrieved between January 1, 2010, and December 31, 2019, from the Web of Science Core Collection database. CiteSpace software facilitated the analysis and visualization of scientific productivity and emerging trends. Nine studies were identified using bibliometric indices, including citation, centrality, and sigma value, which might indicate a growing trend. Through clustering, we identified six major hot subtopics. Using burst analysis, top-5 references with the strongest bursting strength after 2017 were identified, indicating a future hotspot in this field. Current hot subtopics in osteoporotic fracture research include atypical femoral fractures, androgen deprivation therapy, denosumab discontinuation, hip fractures, trabecular bone score (TBS), and bone phenotype. Management and prevention of secondary fractures in patients with osteoporotic fractures, TBSs, and long-term administration strategy for zoledronic acid are expected to become research hotspots.

The correlation between transient osteoporosis of the hip and pregnancy: A review.

Transient osteoporosis of the hip is indubitably a comparatively infrequent entity affecting both men and women worldwide. Its occurrence in the course of pregnancy, specifically in the third trimester, and lactation are of paramount concernment. The exact association between transient hip osteoporosis and pregnancy is precarious. Etiology and potential pathophysiological mechanisms behind this correlation are still to be utterly defined. Magnetic resonance imaging is highly regarded as the gold standard imaging method for assiduous assessment of this disorder. Physicians of copious medical specialties should practice scrupulous techniques for early and pertinent diagnosis when pregnant women are presented with persistent hip pain, as differential diagnosis with femoral head avascular necrosis can be exceedingly arduous. Treatment is predominantly conservative with protected weight-bearing and analgesic medication in the first line of management. In terms of prognosis, the disease ordinarily resolves spontaneously after a few months. Further research is required in order to elucidate the ambiguity surrounding the establishment of globally approved diagnosis and treatment guidelines for pregnancy-associated transient hip osteoporosis. This paper aims to accentuate the significance of this particular disorder by providing a succinct review of the existing literature, augmenting clinicians' knowledge about the features of pregnancy-related transient proximal femur osteoporosis.

Guidelines for diagnosis and treatment of glucocorticoid-induced osteoporosis

Glucocorticoid-induced osteoporosis (GIOP) is a skeletal disease characterized by decreased bone strength and increased fracture risk associated with long-term glucocorticoid use. GIOP is the most common secondary osteoporosis that critically affects the quality of life of patients. Currently, the incidence of GIOP in China remains high, with insufficient awareness and lack of prevention and treatment norms. Therefore, the Chinese Rheumatology Association has established this standard based on domestic and international experience, with the aim of raising awareness of prevention and treatment among clinicians, guiding the standardized diagnosis and treatment of this disease, and improving the overall prognosis of patients with GIOP.

Rosa Maria Rodrigues Pereira (1958-2022).

Her interest in bone metabolism started during her internship in rheumatology; she was particularly intrigued by osteoporosis and the negative effects of corticosteroids on the bone. In the 1990s, she began interacting with the endocrinology service led by Professor Aurelio Borelli, probably the only place in São Paulo University that subscribed to the main journals focused on bone research. Despite her limited experience in a basic research laboratory, she decided to face the challenges of a bench research-based postdoctoral fellowship and joined the laboratory of Professor Ernesto Canalis at Saint Francis Hospital, Hartford, CT, USA. She learned bone cell biology and became proficient with the bench research techniques that she established in her lab in São Paulo after her return to Brazil. She created and directed the Laboratory of Bone Metabolism, which became a center of excellence for training students and young physicians from different specialties. She was able to secure financing to acquire one of the few high-resolution peripheral quantitative computed tomography machines available in Brazil. She became a go-to specialist in rare and challenging bone diseases, many of which made their way into high-impact publications. Prof Pereira developed original research directions and extensively published. Her research focused on bone and mineral disorders related to rheumatic diseases, including pediatric rheumatology and inflammatory vascular diseases. During her career, she published 391 original articles, 85 book chapters, and 8 books. She made major contributions to the use of vitamin D, including a randomized clinical trial, whose results were published in JAMA in 2021, demonstrating that among hospitalized patients with COVID-19, a single high dose of vitamin D3 did not impact the length of hospital stay. Prof Pereira contributed to the development of the Brazilian National Guidelines for Prevention and Treatment of Osteoporosis and was the coordinator of the São Paulo Ageing and Health Study, a population-based prospective cohort study in Brazil, which resulted in more than 17 publications focusing on bone microarchitecture and fragility fractures. The outstanding quality of her work has been recognized by more than 80 national and international awards. She held leadership roles with high-profile journals, including the International Advisory Board of The Lancet Rheumatology, and served as the Regional Editor of Journal of Bone and Mineral Research. Prof Pereira was instrumental in the creation of the Brazilian Association of Bone Assessment and Osteometabolism (ABRASSO) in 2007, contributing to the organization of the scientific program at their conferences, where she proudly showcased the results of her research. Despite her many professional commitments, Prof Pereira was a compassionate physician who was fully dedicated to patients with rheumatologic diseases during her 40-year career. She led weekly rheumatology rounds and inspired many students and residents who had the fortune of coming under her wings during her 4-decade-long career. Prof Pereira mentored 7 postdoctoral students, 33 doctoral students, 5 master's degree students, and 22 undergraduate students. They will certainly continue to have the legacy of patient care and academic excellence. Prof Pereira was tireless and determined. Her work schedule included weekdays and weekends; she continued her hectic schedule until just a few weeks before she was overcome by illness. Prof Pereira exemplifies how effective leadership can have long-lasting positive effects on others and on our field at large. Her work and legacy will remain a source of inspiration for new generations of clinicians and researchers who will continue to advance our knowledge of rheumatology and metabolic bone diseases. Prof Pereira will be missed by her family, many lifelong colleagues, friends, and patients. She is survived by her husband, Ricardo, a great motivator and supporter of her academic career. We are now committed to turning sadness into a strength and celebrating Prof Pereira's personal and scientific legacy. The peer review history for this article is available at https://publons.com/publon/10.1002/jbmr.4767. The peer review history for this article is available at https://publons.com/publon/10.1002/jbmr.4767.

Research Progress of Male Osteoporotic Fracture

The diagnosis and recognition of male osteoporosis is still insufficient. The male patients with low-energy fracture were less evaluated and treated for osteoporosis. The risk of osteoporotic fracture in elderly men may be between 13% and 25%. With the extension of men’s life, the risk of fracture increases, which makes the management of men with fracture risk challenging. A consensus is emerging on targeted treatment guidelines for male osteoporosis, especially for elderly patients with high fracture risk. This paper aims to seek evidence through literature review, and put forward the most effective clinical strategies and schemes for the diagnosis and treatment of senile osteoporosis, so as to provide some theoretical guidance for clinical practice.

Federal clinical guidelines for diagnosis, treatment and prevention of osteoporosis

Due to continuous aging of population and increase in the number of elderly people, osteoporosis became socially significant disease leading to disability, increasing mortality and thereby putting an additional burden on the public healthcare system.Screening to identify groups with a high probability of fracture is recommended using the FRAX®Tool for all postmenopausal women and men over 50 years old (А1). In the presense of major pathological fractures (hip, spine, multiple fractures) it is recommended to diagnose osteoporosis and prescribe treatment regardless of the results of spine and hip double X-ray absorptiometry (DXA) or FRAX®(B2).It is recommended to evaluate C-terminal telopeptide when prescribing antiresorptive therapy and procollagen type 1 N-terminal propeptide (P1NP) when prescribing anabolic therapy to patients receiving osteoporosis treatment at baseline and 3 months after the start of therapy in order to assess the effectiveness of treatment early and adherence to the therapy (А2). It is recommended to diagnose osteoporosis and prescribe treatment to patients with high individual 10-year probability of major pathological fractures (FRAX®) regardless of the results of spine and hip DXA (В3).It is recommended to diagnose osteoporosis and prescribe treatment with a decrease in BMD, measured by DXA, by 2.5 or more T-score standard deviations in femoral neck, and/or in total hip, and/or in lumbar vertebrae, in postmenopausal women and men over 50 years old (А2).It is recommended to prescribe bisphosphonates, denosumab or teriparatide to prevent pathological fractures and increase BMD in patients with postmenopausal osteoporosis, osteoporosis in men, glucocorticoid-induced osteoporosis (А2). When the clinical effect of therapy in osteoporotic patients without pathological fractures is achieved (BMD T-score > -2.0 SD in femoral neck and absence of new fractures), it is recommended to interrupt bisphosphonates therapy for 1-2 years with subsequent follow-up (B2). In patients with vertebral fractures, hip fractures or multiple fractures, it is recommended to continue ceaseless long-term treatment of osteoporosis (В3).All drugs for the treatment of osteoporosis are recommended to be prescribed in combination with calcium and cholecalciferol (А2). In order to reduce the risk of recurrent fractures by prescribing osteoporosis therapy timely and maintaining long-term follow-up of patients over 50 years old with pathological fractures, it is recommended to create Fracture Liaison Services (В2).

Congress of Neurological Surgeons Systematic Review and Evidence-Based Guidelines for Perioperative Spine: Preoperative Osteoporosis Assessment.

Osteoporosis is a metabolic bone disease that commonly affects the elderly. Degenerative spinal disease that may require surgical intervention is also prevalent in this susceptible population. If undiagnosed or untreated before spine surgery, osteoporosis may result in an increased risk of postoperative adverse events. Nontreatment of osteoporosis preoperatively may be related to a poor understanding of bone physiology, a lack of standardized treatment algorithms, limited cost-effective interventions, and reluctance by spine surgeons to be the primary provider of osteoporosis management. The objective of this evidence-based review is to develop guidelines for the preoperative assessment and treatment of osteoporosis in patients undergoing spine surgery. A systematic review of the literature was performed using the National Library of Medicine/PubMed database and Embase for studies relevant to preoperative diagnostic studies that predict increased risk of osteoporosis-related postoperative adverse events and whether the preoperative treatment of low bone mineral density (BMD) in patients with osteoporosis improves outcome. Out of 281 studies, 17 met the inclusion criteria and were included for systematic review. The task force affirmed a Grade B recommendation that preoperative osteoporosis testing with a dual-energy X-ray absorptiometry scan (T-score < -2.5), a computed tomography scan (Hounsfield units <97.9), and serum vitamin D3 level (<20ng/mL) predict an increased risk of osteoporosis-related adverse events after spine surgery. The task force determined a Grade B recommendation that preoperative osteoporosis treatment with teriparatide increases BMD, induces earlier and more robust fusion, and may improve select patient outcomes. There is insufficient evidence regarding preoperative treatment with bisphosphonates alone and postoperative outcome. This evidence-based clinical guideline provides a recommendation that patients with suspected osteoporosis undergo preoperative assessment and be appropriately counseled about the risk of postoperative adverse events if osteoporosis is confirmed. In addition, preoperative optimization of BMD with select treatments improves certain patient outcomes.The full guidelines can be accessed at https://www.cns.org/guidelines/browse-guidelines-detail/3-preoperative-osteoporosis-assessment.

Heavy clinical and economic burden of osteoporotic fracture among elderly female Medicare beneficiaries.

Postmenopausal women with osteoporosis are stratified to high and very-high fracture risk categories, and this categorization drives algorithms for osteoporosis management in osteoporosis treatment guidelines. This study comprehensively describes a very-high-risk cohort. This retrospective cohort study used the Medicare 20% database; elderly women with an outpatient visit in 2011 and fracture within 2 years before the visit were included. Outcomes included fracture risk, all-cause and fracture-related healthcare resource utilization and cost, and osteoporosis medication use in the 5 years after the visit. Overall, 43,193 patients were included. The 5-year probability was 0.36 for major fracture and 0.11 and 0.17 for hip fracture and vertebral fracture, respectively, much higher than the guidelines' 10-year probability thresholds for very-high-risk (0.3 for major fracture, 0.045 for hip fracture). Rates of hospitalizations, emergency department visits or observation stays, and skilled nursing facility stays in year 1 were 53.7, 57.0, and 18.8 per 100 patient-years, respectively, decreasing slightly in subsequent years. Mean healthcare cost was $23,700 in year 1, decreasing to $18,500 in year 5. About 29.1% of patients received osteoporosis medications in year 1, decreasing to 16.9% by year 5. Rates for all outcomes, especially fractures, were much higher among vertebral and multiple fracture cohorts. Elderly women with a fracture within last 2 years were at very-high-risk for subsequent fracture and high healthcare utilization and cost, especially those with vertebral or multiple fractures. However, rates of fracture prevention treatments were low. More effort is needed to identify and treat patients at very-high-risk for fracture.

Low Bone Mineral Density and Recurrent Fractures During and After Pregnancy: Dilemma of an Overlooked Diagnosis

Background: Decreased bone mineral density (BMD) during pregnancy and lactation are rarely described in literature. We present this case of multiple compression fractures during and after pregnancy, highlighting the diagnostic and therapeutic dilemma of an overlooked diagnosis. Clinical Case: A 23-year-old female without significant past medical history, suffers from an acute onset lower back pain in the third trimester of her first pregnancy. On initial evaluation, this back pain was thought to be musculoskeletal and was dismissed by her medical team. No imaging was ordered throughout the duration of pregnancy, despite the pain remaining unrelenting. On her second day post-partum, she heard a “pop” in her back and fell while holding her newborn. Imaging revealed multiple vertebral compression fractures, in different stages of acuity. Due to debilitating pain, the patient quit breastfeeding and ultimately would never hold her baby again. Her simple activities of daily living were stymied, both as a mother and secretary. It wasn’t long before she couldn’t even fax forms in her office and had to leave work with debility. Traumatized by these life events and continuing to be afflicted by this chronic pain, the patient decided against having any future children. Her compression fractures were managed with different types of analgesics in addition to vitamin D and calcium supplements.At age 53 and 57, BMD scans showed a T-score >1 at both the lumbar spine and total hip. Forearm BMD was not evaluated at these times. At age 58, a CT spine demonstrated new compression fractures at T5-T12 & L1-L5. She subsequently underwent kyphoplasty of T5, T7 and T8. Fortunately, a bone core biopsy of these 3 vertebrae showed no malignant pathology. A follow up CT scan 6 months later showed stable compression fractures, along with multilevel degenerative changes and neural foraminal stenosis. At age 60, the patient would receive L4-L5 trans-foraminal epidural corticosteroid injection and referral to the bone clinic at a tertiary health center. Initial lab work on referral was significant for normal calcium, albumin, parathyroid hormone, vitamin D, kidney function, liver function, serum and urine protein electrophoresis and cross link N-telopeptide. Osteocalcin was low at 3.9 ng/mL (NL 8.8–37.6 ng/mL). Repeat BMD scan showed T-scores of 0.6, 1.1 and -2.6 at her lumbar spine, total hip and distal forearm respectively. Her osteoporosis is currently managed with teriparatide without active issues. Conclusion: This case highlights the rare development of low BMD in pregnant and breastfeeding women, without prior risk factors, jeopardizing future quality of life. The evidence behind the incidence and pathophysiology underlying these changes remains deficient. There remains a dearth of guidelines for definition and treatment of osteoporosis and low BMD in young peripartum women.

FRAX-based osteoporosis treatment guidelines for resource-poor settings in India.

Our study aimed to formulate population-specific intervention thresholds for treatment of osteoporosis in India which can be used even without dual X-ray absorptiometry (DXA). Using the FRAX® model for India, thresholds for different age groups for men and women were calculated without bone mineral density (BMD) measurement. The lower assessment threshold (LAT) was based on the 10-year probability of a major osteoporosis fracture (MOF) or hip fracture (HF) equivalent to patients without clinical risk factors. The intervention threshold (IT) was based on the 10-year probability equivalent to patients with fracture. The upper assessment threshold (UAT) was set at 1.2 times the IT. Probability-based thresholds for no intervention (LAT), treatment initiation (UAT) and BMD assessment (between LAT and UAT) were derived. The thresholds were validated in a cohort of 300 patients who were referred for BMD testing. Graphs for age, gender, BMI and ethnic-specific LAT, IT and UAT for MOF and HF are derived. In the validation cohort, BMD testing to initiate/defer treatment was required in only 32.3% patients. The intervention thresholds derived without BMD testing were valid in 98.7% patients. Use of National Osteoporosis Foundation (NOF) guidelines would have resulted in overtreatment in 56/300 (18.6%) patients. We suggest the use of this newer age and ethnic-specific FRAX®-derived thresholds for management of osteoporosis. Adopting these cut-offs will ensure that those requiring osteoporosis treatment will not be denied of it just because of lack of a DXA machine and will also help avoid overtreatment.

Atypical femoral fracture after discontinuing long-term bisphosphonate use

Agents that slow bone resorption (antiresorptive) and increase bone formation (anabolic) are used as medical treatment modalities in osteoporosis. Bisphosphonates (BP) are antiresorptive drugs that suppress osteoclastic activity and slow bone resorption and are recommended to be used as first-line therapy in osteoporosis treatment guidelines. For two decades, these drugs have been prescribed in our country and worldwide to treat osteoporosis and reduce the risk of fractures. However, according to the literature, atypical femoral fractures (AFF) are encountered in patients who have been using these drugs for more than five years. In this case report, we present the diagnosis, treatment, and recovery process of a patient who developed AFF after discontinuing long-term use of BP.

High prevalence of female osteoporosis and male osteopenia in patients aged more than 55 years old with upper limb fracture

Introduction: According to literature and osteoporosis treatment guidelines, both men and women with distal radius fractures (DRFx) and proximal humerus fractures (PHFx) caused by low-energy trauma may have undetected osteoporosis. Although upper limb fracture is a known predictor of subsequent osteoporotic fracture, the rates of prompt bone mineral density (BMD) evaluation and antiosteoporotic management in these patients remains much lower than those in patients with hip or spine fractures. Purpose: To evaluate the awareness of the physician for survey osteoporosis and to identify the association of the aforementioned fractures after falls with osteoporosis based on BMD estimated through dual-energy X-ray absorptiometry. Methods: We collected the parameters, including ethnicity, comorbidities, age, sex, and BMD data of the patients aged ≥ 55 years who sustained DRFx or PHFx and their BMD examination rates as physician awareness rate of possible osteoporosis. The incidence of osteoporosis among patients with these fractures was compared and associated risk factors were identified. Results: The physician awareness rates were 65.1% in DRFx and 66.0% in PHFx. Four hundred and twenty-one patients with DRFx and 219 patients with PHFx were included. Of the patients, 239 were male and 401 were female, and their mean age was 67.1 ± 6.5 years. The osteoporosis rates were 38.0% and 46.6% in DRFx and PHFx. No patient aged more than 70 years had normal BMD in our study group. Most female patients had osteoporosis, whereas most male patients had osteopenia. 7.7% of the patients had normal T scores and only 24.6% of the patients with osteoporosis were undergoing regular antiosteoporotic treatment and follow-up. Those with PHFx had a significantly higher osteoporosis risk than did those with DRFx. Conclusion: Osteoporosis awareness and treatment are crucial after distal radius or PHFx in addition to hip fractures, particularly for female and older patients.

Bone Health Management After Hematopoietic Cell Transplantation: An Expert Panel Opinion from the American Society for Transplantation and Cellular Therapy.

Bone health disturbances commonly occur after hematopoietic cell transplantation (HCT) with loss of bone mineral density (BMD) and avascular necrosis (AVN) foremost among them. BMD loss is related to pretransplantation chemotherapy and radiation exposure and immunosuppressive therapy for graft-versus-host-disease (GVHD) and results from deficiencies in growth or gonadal hormones, disturbances in calcium and vitamin D homeostasis, as well as osteoblast and osteoclast dysfunction. Although the pathophysiology of AVN remains unclear, high-dose glucocorticoid exposure is the most frequent association. Various societal treatment guidelines for osteoporosis exist, but the focus is mainly on menopausal-associated osteoporosis. HCT survivors comprise a distinct population with unique comorbidities, making general approaches to bone health management inappropriate in some cases. To address a core set of 16 frequently asked questions (FAQs) relevant to bone health in HCT, the American Society of Transplant and Cellular Therapy Committee on Practice Guidelines convened a panel of experts in HCT, adult and pediatric endocrinology, orthopedics, and oral medicine. Owing to a lack of relevant prospective controlled clinical trials that specifically address bone health in HCT, the answers to the FAQs rely on evidence derived from retrospective HCT studies, results extrapolated from prospective studies in non-HCT settings, relevant societal guidelines, and expert panel opinion. Given the heterogenous comorbidities and needs of individual HCT recipients, answers to FAQs in this article should be considered general recommendations, with good medical practice and judgment ultimately dictating care of individual patients. Readers are referred to the Supplementary Material for answers to additional FAQs that did not make the core set.

Mapping theme trends and recognizing hot spots in postmenopausal osteoporosis research: a bibliometric analysis.

BackgroundThis study aimed to draw a series of scientific maps to quantitatively and qualitatively evaluate hot spots and trends in postmenopausal osteoporosis research using bibliometric analysis.MethodsScientific papers published on postmenopausal osteoporosis were extracted from the Web of Science Core Collection and PubMed database. Extracted information was analyzed quantitatively with bibliometric analysis by CiteSpace, the Online Analysis Platform of Literature Metrology and Bibliographic Item Co-Occurrence Matrix Builder (BICOMB). To explore the hot spots in this field, co-word biclustering analysis was conducted by gCLUTO based on the major MeSH terms/MeSH subheading terms-source literatures matrix.ResultsWe identified that a total of 5,247 publications related to postmenopausal osteoporosis were published between 2013 and 2017. The overall trend decreased from 1,071 literatures in 2013 to 1,048 literatures in 2017. Osteoporosis International is the leading journal in the field of postmenopausal osteoporosis research, both in terms of impact factor score (3.819) and H-index value (157). The United States has retained a top position and has exerted a pivotal influence in this field. The University of California, San Francisco was identified as a leading institution for research collaboration, and Professors Reginster and Kanis have made great achievements in this area. Eight research hot spots were identified.ConclusionsOur study found that in the past few years, the etiology and drug treatment of postmenopausal osteoporosis have been research hot spots. They provide a basis for the study of the pathogenesis of osteoporosis and guidelines for the drug treatment of osteoporosis.

Pharmacological Management of Osteoporosis in Rheumatoid Arthritis Patients: A Review of the Literature and Practical Guide.

Rheumatoid arthritis (RA) is a chronic disabling disease that is associated with increased localized and generalized osteoporosis (OP). Previous studies estimated that approximately one-third of the RA population experience bone loss. Moreover, RA patients suffer from a doubled fracture incidence depending on several clinical factors, such as disease severity, age, glucocorticoid (GC) use, and immobility. As OP fractures are related to impaired quality of life and increased mortality rates, OP has an enormous impact on global health status. Therefore, there is an urgent need for a holistic approach in daily clinical practice. In other words, both OP- and RA-related factors should be taken into account in treatment guidelines for OP in RA. First, to determine the actual fracture risk, dual-energy X-ray absorptiometry (DXA), including vertebral fracture assessment (VFA) and calculation of the 10-year fracture risk with FRAX®, should be performed. In case of high fracture risk, calcium and vitamin D should be supplemented alongside anti-osteoporotic treatment. Importantly, RA treatment should be optimal, aiming at low disease activity or remission. Moreover, GC treatment should be at the lowest possible dose. In this way, good fracture risk management will lead to fracture risk reduction in RA patients. This review provides a practical guide for clinicians regarding pharmacological treatment options in RA patients with OP, taking into account both osteoporotic-related factors and factors related to RA.

Teriparatide Improves Bone and Lipid Metabolism in a Male Rat Model of Type 2 Diabetes Mellitus.

Osteoporosis is a complication of diabetes mellitus (DM). The pathology of diabetic osteoporosis is distinct from postmenopausal osteoporosis, and there are no specific treatment guidelines for diabetic osteoporosis. In the current study, this issue was addressed by evaluating the effect of osteoporosis medications, such as the anabolic agent PTH [teriparatide (TPTD)] and the antiresorptive agents calcitonin [elcatonin (ECT)] and bisphosphonate [risedronate (RIS)], on bone metabolism as well as on glucose and lipid metabolism in spontaneously diabetic Torii (SDT) fatty rats, which are a model of type 2 DM (T2DM). The medicines were injected subcutaneously into 8-week-old male SDT fatty rats three times weekly for 8 weeks. TPTD treatment in SDT fatty rats increased the osteoblast number and function on trabecular bone in vertebrae, and increased the trabecular bone mass, bone mineral density (BMD), and mechanical strength of vertebrae. Additionally, TPTD improved cortical bone structure and increased BMD. RIS decreased the osteoclast number and function, which led to an increase in vertebral bone mineral content and BMD in the femoral diaphysis, and mechanical strength was increased in the vertebrae. ECT showed no clear effects on bone mass or metabolism. Similar to diabetic lesions, all of the drugs had no effects on hyperglycemia, pancreas morphology, or serum insulin and glucagon levels. However, triglyceride levels and lipid droplets in fatty liver were decreased in the TPTD group. These results suggest that TPTD may be useful for treating fatty liver in addition to osteoporosis in T2DM.

We miss the opportunity: Pretreament of osteoporosis in a German trauma center.

Osteoporosis remains a major health concern due to high incidence of fragility fractures followed by higher mortality and morbidity. Implementation of guidelines for diagnosis and treatment of osteoporosis is critically discussed internationally. Aim of this study was to evaluate implementation of these guidelines regarding diagnosis and therapy of osteoporosis in a developed western country. We hypothesized that (a) prior diagnosis of osteoporosis in patients with low-energy fractures is higher than the estimated incidence and (b) diagnosis and therapy of osteoporosis in patients with prior low-energy fractures is higher than in patients without prior low-energy fractures. 399 patients >60 years suffering low-energy-fractures of their spine, femur, humerus or forearm between 03/2014 and 04/2015 were recruited in a German trauma center. All received a standardized interview. In 21% (84/399) of all patients, osteoporosis was diagnosed prior to current admission. 34% (136/399) suffered a prior risk-fracture after age of 50. Of these, only 54% (73/136) reported about following dual-energy X-ray absorptiometry (DXA) to test for decreased bone-marrow-density with positive results in 68% (50/73). 38% (19/50) of these patients with fragility fractures and prior osteoporosis diagnosis received anti-osteoporotic medication. 66% (263/399) of all patients had no prior risk-fracture and were tested for osteoporosis by DXA in 36% (95/263), leading to positive results in 34% (32/95). 44% (14/32) of these patients received anti-osteoporotic medication. Applying FRAX, 33% of all patients showed a calculated 10-year-risk >20% for suffering a major osteoporotic fracture. 61% (83/136) of patients with a prior fracture had a 10-year-risk >20% of which 47% (39/83) patients received no prior DXA. Although guidelines recommend diagnosis and treatment of patients with low-energy fractures, opportunity for early treatment following risk fractures seems rarely used. Expedient risk assessment is necessary to indicate further diagnostics and therapy of osteoporosis to ensure adequate and efficient treatment for osteoporotic fractures.

Glucocorticoids, Inflammation and Bone.

The current review on glucocorticoids (GCs), inflammation and bone is focused on three aspects: (1) the mutual effects between GCs, inflammation and bone in inflammatory rheumatic diseases, (2) current views on fracture risk assessment in patients using GCs and (3) non-pharmacological and pharmacological treatment to prevent fractures in GC-using patients with inflammatory rheumatic diseases. The use of GCs results in increased risk for fractures due to both direct and indirect negative effects of GCs on bone mass, and on bone and muscle strength. However, also the underlying inflammatory rheumatic disease is associated with the increased bone loss and fracture risk due to the chronic inflammation itself, and due to disability/immobility caused by active disease or joint destruction. The rapid and strong anti-inflammatory effect of GCs in patients with rheumatoid arthritis seems to balance the negative effects of GCs on bone in the early, active phase of the disease. Recently, an update of the American College of Rheumatology guidelines for prevention and treatment of GC-induced osteoporosis was published with renewed recommendations. To prevent fractures, general measures, including treatment of the underlying inflammatory disease adequately (even with GCs when indicated), a healthy lifestyle, including adequate calcium and vitamin D supplementation, and regular weight bearing exercises are important. In rheumatic patients with high fracture risk using GCs, especially when the cumulative dose is high and/or the underlying inflammatory disease is active, treatment with anti-osteoporotic drugs, usually an oral bisphosphonate, is indicated.

The FRAX-based Lebanese osteoporosis treatment guidelines: rationale for a hybrid model.

The FRAX risk calculator is used to guide intervention thresholds in several national osteoporosis guidelines. This study aimed to describe the approach in developing FRAX-based osteoporosis treatment guidelines in Lebanon, a country with relatively low fracture rates. We reassessed previous national guidelines combined with an evaluation of age-dependent and fixed FRAX-based intervention threshold models used in the UK, the USA, and Canada. We took into consideration the risk for major osteoporotic fractures (MOF) and the proportions of subjects considered for therapy using such thresholds, before finalizing a model for Lebanon. The new Lebanese guidelines retained the recommendation to treat individuals with fragility fracture at the hip or spine. A femoral neck T-score ≤-2.5 in subjects without fractures was dropped, since it would imply consideration of therapy for individuals with a 10-year risk for MOF of <10%, up to age 75years in women. After considering the impact of both age-dependent and fixed intervention thresholds, we chose a new hybrid algorithm, combining a fixed 10% treatment threshold until age 70years and an age-dependent threshold thereafter. The Lebanese FRAX-based hybrid model takes into consideration the risk for MOF and the proportions of subjects considered for treatment. This model avoids consideration of drug therapy in a large proportion of younger subjects at low risk for fracture and targets high risk elderly individuals. It was deemed most suitable for Lebanon and may be an option for other countries with relatively low fracture rates.

On "2015 Guidelines for Prevention and Treatment of Osteoporosis". Medical treatment for osteoporosis

The main revisions to the item of medical treatment in the 2015 edition of the Guidelines for Prevention and Treatment of Osteoporosis are the additions of the drugs such as ibandronate, teriparatide acetate (once-weekly preparation), and denosumab, which were approved after the release of the 2011 edition, and of information on new dosage forms for existing drugs. Furthermore, the heading "Evaluation and Recommendations" for each drug was changed to "Evaluation of Efficacy" . The choice of drug is determined based on evidence for the effectiveness of each drug and in accordance with the age, fracture risk, and pathophysiology of each patient. As for the selection and combined use of the various drugs, accumulation of evidence is anticipated, but sequential therapy using antiresorptive agents following treatment with teriparatide preparations is recommended.